Blueprint Medicines has been granted a patent for crystalline forms of Compound (I) for treating disorders associated with oncogenic KIT and PDGFRA alterations. The patent includes methods for making the compound and pharmaceutical compositions. GlobalData’s report on Blueprint Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Blueprint Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Blueprint Medicines's grant share as of May 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of systemic mastocytosis with crystalline form a of compound (i)
A recently granted patent (Publication Number: US11999744B2) discloses a method for treating systemic mastocytosis by administering a therapeutically effective amount of crystalline Form A of Compound (I). The crystalline Form A is characterized by specific X-ray powder diffractogram patterns, including peaks at precise 2? angles, and a distinctive DSC thermogram with specific temperature ranges. The method is applicable to various forms of systemic mastocytosis, such as smoldering systemic mastocytosis (SSM), advanced systemic mastocytosis (AdvSM), aggressive systemic mastocytosis (ASM), systemic mastocytosis associated with hematological non-mast cell lineage disease (SM-AHN), mast cell leukemia (MCL), and indolent systemic mastocytosis (ISM).
Furthermore, the method is particularly effective for patients with specific mutations in Exon 17 of the KIT gene, such as the D816 mutation, including the D816V variant. The patent also specifies the dosage of 200 mg of Crystalline Form A of Compound (I) to be administered once daily to the patient. This innovative treatment approach offers a targeted therapeutic solution for systemic mastocytosis, addressing different subtypes and genetic mutations associated with the disease, thereby potentially improving patient outcomes and quality of life.
To know more about GlobalData’s detailed insights on Blueprint Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
